A case of de novo splice site variant in SLC35A2 showing developmental delays, spastic paraplegia, and delayed myelination
暂无分享,去创建一个
Y. Wada | N. Okamoto | H. Osaka | H. Saitsu | M. Nakashima | Toshiyuki Yamamoto | K. Kurosawa | Ken Inoue | J. Takanashi | T. Ohashi | Sachiko Miyamoto | Takuya Hiraide | Takehiro Miyazaki
[1] J. Rosenfeld,et al. SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals , 2019, Human mutation.
[2] M. Farrer,et al. Diagnostic Yield and Treatment Impact of Targeted Exome Sequencing in Early-Onset Epilepsy , 2019, Frontiers in neurology.
[3] B. D. de Vries,et al. Clinical, neuroradiological, and biochemical features of SLC35A2‐CDG patients , 2019, Journal of inherited metabolic disease.
[4] Jae Seok Lim,et al. Brain somatic mutations in SLC35A2 cause intractable epilepsy with aberrant N-glycosylation , 2018, Neurology: Genetics.
[5] R. Møller,et al. SLC35A2-related congenital disorder of glycosylation: Defining the phenotype. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[6] H. Reddi,et al. Retrospective genotype-phenotype analysis in a 305 patient cohort referred for testing of a targeted epilepsy panel , 2018, Epilepsy Research.
[7] E. I. Pierpont,et al. Mosaicism of the UDP-Galactose transporter SLC35A2 in a female causing a congenital disorder of glycosylation: a case report , 2018, BMC medical genetics.
[8] C. Schevon,et al. Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy , 2018, Annals of neurology.
[9] T. Ogata,et al. De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism , 2018, Human Genetics.
[10] N. Matsumoto,et al. A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy , 2017, Brain and Development.
[11] Michael R. Johnson,et al. Erratum: De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies (American Journal of Human Genetics (2014) 95(4) (360–370)(S0002929714003838)(10.1016/j.ajhg.2014.08.013)) , 2017 .
[12] R. Pfundt,et al. Novel genetic causes for cerebral visual impairment , 2015, European Journal of Human Genetics.
[13] Michael J E Sternberg,et al. The Phyre2 web portal for protein modeling, prediction and analysis , 2015, Nature Protocols.
[14] K. Nakayama,et al. Genomic analysis identifies candidate pathogenic variants in 9 of 18 patients with unexplained West syndrome , 2015, Human Genetics.
[15] Y. Wada,et al. A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach , 2015, Journal of Inherited Metabolic Disease.
[16] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[17] J. Tiralongo,et al. Structure and function of nucleotide sugar transporters: Current progress , 2014, Computational and structural biotechnology journal.
[18] Christian H. Ahrens,et al. Protter: interactive protein feature visualization and integration with experimental proteomic data , 2014, Bioinform..
[19] Y. Wada,et al. De Novo Mutations in SLC35A2 Encoding a UDP‐Galactose Transporter Cause Early‐Onset Epileptic Encephalopathy , 2013, Human mutation.
[20] Huijong Han,et al. Myelin‐specific proteins: A structurally diverse group of membrane‐interacting molecules , 2013, BioFactors.
[21] Emily H Turner,et al. Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation. , 2013, American journal of human genetics.
[22] H. Freeze. Understanding Human Glycosylation Disorders: Biochemistry Leads the Charge* , 2013, The Journal of Biological Chemistry.
[23] A. Ishii,et al. Oligodendrocyte development and myelin biogenesis: parsing out the roles of glycosphingolipids. , 2009, Physiology.
[24] M. Kawakita,et al. Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35) , 2004, Pflügers Archiv.
[25] H. R. Bergen,et al. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. , 2001, Clinical chemistry.
[26] Y. Hirabayashi,et al. Glucosylceramide synthase and glycosphingolipid synthesis. , 1998, Trends in cell biology.
[27] H. Zoghbi,et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. , 1992, American journal of human genetics.